

## Diagnosis & staging

**39,409** people were diagnosed with lung cancer in 2024

36,557 in 2023 & 36,160 in 2022

51% female

74  
years

49% male

median age at diagnosis

40%  of patients were diagnosed at stage 1-2  
36% in 2023 & 32% in 2022

41%  of patients presented with stage 4 lung cancer  
44% in 2023 & 47% in 2022

30%  of patients were diagnosed after emergency admission  
32% in 2023 & 33% in 2022

**Key**

  improving from 2023  
  worsening from 2023  
 unchanged from 2023

## Waiting times in Non-small Cell Lung Cancer (NSCLC)

81  
days

Median time from referral to surgery in NSCLC stage 1-2

83 days in 2023

63  
days

Median time from referral to SACT in NSCLC stage 3B-4

66 days in 2023

## Treatment allocation

### Treatment with curative intent for Non-Small Cell Lung Cancer (NSCLC)

79%  of patients with NSCLC (stage 1-2, Performance Status (PS) 0-2) received treatment with curative intent\*



\*surgery or radical radiotherapy

**≥80%**  
Audit standard

80% in 2023  
80% in 2022

59%  of patients with NSCLC (stage 3A, PS 0-2) received treatment with curative intent\*\*



N/A

62% in 2023  
61% in 2022

\*\*surgery, radical radiotherapy or multimodal treatment

### Surgery for Non-Small Cell Lung Cancer (NSCLC)

22%  of patients with NSCLC had surgical treatment for their cancer



Absolute number of surgeries in 2024: 7,878

**≥17%**  
Audit standard

20% in 2023  
18% in 2022

### Systemic Anti-Cancer Therapy (SACT) for Non-Small Cell Lung Cancer (NSCLC)

63%  of patients with NSCLC (stage 3B-4, PS 0-1) received SACT



**≥70%**  
Audit standard

63% in 2023  
63% in 2022

### Systemic Anti-Cancer Therapy (SACT) for Small Cell Lung Cancer (SCLC)

71%  of patients with SCLC received treatment with SACT



Median time from 'decision to treat' to start SACT: 16 days

**≥70%**  
Audit standard

74% in 2023  
73% in 2022

## Survival outcomes

19,326 patients were diagnosed between 1 January and 30 June 2024. For these patients:

### Median survival

372  
days  


349 days in 2023  
281 days in 2022

### One year survival

51%  49% in 2023  
45% in 2022

## Data quality

### Completeness of key routine data items

#### Stage

93%

90%  


#### Performance status

89%  


#### Basis of diagnosis

92%  


#### Morphology

64%  


#### Lung Clinical Nurse Specialist at diagnosis

64%  


#### Smoking status

46%  


90%  
